

The Japanese version of this document is the authoritative version, and this English translation is intended for reference purposes only. Should any discrepancies or doubts arise between the two versions, the Japanese version shall prevail.

Basic policies for supplying the iPS Cell stock

The CiRA Foundation maintains an iPS cell stock. This stock is used to generate and supply medically-applicable iPS cells for the research and development of cell transplantation therapy, etc., and eventually contribute to the development of regenerative medicine for patients suffering from intractable diseases and injuries.

To achieve this aim and promote appropriate use of the iPS cell stock, the CiRA Foundation supplies it in accordance with the following basic policies.

1. For both profit making and non-profit making, use of the iPS cell stock should be approved for research or business that is in accordance with the aim of the iPS Cell Stock Project and within the scope of the consent obtained from donors.
2. The iPS cell stock should be supplied to research institutions or companies that are proven to have the appropriate implementation system. Examination methods, etc., for the supply should be separately stipulated.
3. In supplying the iPS cell stock, the greatest consideration should be given to the protection of personal information and privacy of donors and their close relatives.